Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial.

Rabe KF, Fabbri LM, Vogelmeier C, Kögler H, Schmidt H, Beeh KM, Glaab T.

Chest. 2013 Mar;143(3):711-719. doi: 10.1378/chest.12-1277.

PMID:
23188489
2.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
3.

Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).

Vogelmeier CF, Asijee GM, Kupas K, Beeh KM.

Adv Ther. 2015 Jun;32(6):537-47. doi: 10.1007/s12325-015-0216-2. Epub 2015 Jun 23.

4.

Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.

Rabe KF, Fabbri LM, Israel E, Kögler H, Riemann K, Schmidt H, Glaab T, Vogelmeier CF.

Lancet Respir Med. 2014 Jan;2(1):44-53. doi: 10.1016/S2213-2600(13)70248-0. Epub 2013 Dec 5.

PMID:
24461901
5.

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.

Chong J, Karner C, Poole P.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009157. doi: 10.1002/14651858.CD009157.pub2. Review.

PMID:
22972134
6.

Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.

Cheyne L, Irvin-Sellers MJ, White J.

Cochrane Database Syst Rev. 2015 Sep 22;(9):CD009552. doi: 10.1002/14651858.CD009552.pub3. Review.

PMID:
26391969
7.

Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.

Cheyne L, Irvin-Sellers MJ, White J.

Cochrane Database Syst Rev. 2013 Sep 16;(9):CD009552. doi: 10.1002/14651858.CD009552.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;(9):CD009552.

PMID:
24043433
8.

Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium.

Tashkin DP.

Int J Chron Obstruct Pulmon Dis. 2010 Feb 18;5:41-53. Review.

9.

Risk indexes for exacerbations and hospitalizations due to COPD.

Niewoehner DE, Lokhnygina Y, Rice K, Kuschner WG, Sharafkhaneh A, Sarosi GA, Krumpe P, Pieper K, Kesten S.

Chest. 2007 Jan;131(1):20-8.

PMID:
17218552
10.

Aclidinium bromide for stable chronic obstructive pulmonary disease.

Ni H, Soe Z, Moe S.

Cochrane Database Syst Rev. 2014 Sep 19;(9):CD010509. doi: 10.1002/14651858.CD010509.pub2. Review.

PMID:
25234126
11.

Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.

Beeh KM, Glaab T, Stowasser S, Schmidt H, Fabbri LM, Rabe KF, Vogelmeier CF.

Respir Res. 2013 Oct 29;14:116. doi: 10.1186/1465-9921-14-116.

12.

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.

Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, Cassino C, Kesten S.

Ann Intern Med. 2005 Sep 6;143(5):317-26.

PMID:
16144890
13.

Tiotropium versus placebo for chronic obstructive pulmonary disease.

Karner C, Chong J, Poole P.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD009285. doi: 10.1002/14651858.CD009285.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(7):CD009285.

PMID:
22786525
14.

Tiotropium versus placebo for chronic obstructive pulmonary disease.

Karner C, Chong J, Poole P.

Cochrane Database Syst Rev. 2014 Jul 21;(7):CD009285. doi: 10.1002/14651858.CD009285.pub3. Review.

PMID:
25046211
15.

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators.

N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.

16.

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium.

Ann Intern Med. 2007 Apr 17;146(8):545-55. Epub 2007 Feb 19.

PMID:
17310045
17.

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.

Farne HA, Cates CJ.

Cochrane Database Syst Rev. 2015 Oct 22;(10):CD008989. doi: 10.1002/14651858.CD008989.pub3. Review.

PMID:
26490945
18.

Efficacy of tiotropium in the prevention of exacerbations of COPD.

Anzueto A, Miravitlles M.

Ther Adv Respir Dis. 2009 Jun;3(3):103-11. doi: 10.1177/1753465809338854. Epub 2009 Jul 17. Review.

PMID:
19617284
19.

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations.

Beeh KM, Hederer B, Glaab T, Müller A, Rutten-van Moelken M, Kesten S, Vogelmeier C.

Int J Chron Obstruct Pulmon Dis. 2009;4:119-25. Epub 2009 Apr 15.

20.

Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial.

Tashkin D, Celli B, Kesten S, Lystig T, Decramer M.

Respir Med. 2010 Oct;104(10):1495-504. doi: 10.1016/j.rmed.2010.03.033. Epub 2010 Apr 24.

Supplemental Content

Support Center